JP2004533401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533401A5 JP2004533401A5 JP2001586308A JP2001586308A JP2004533401A5 JP 2004533401 A5 JP2004533401 A5 JP 2004533401A5 JP 2001586308 A JP2001586308 A JP 2001586308A JP 2001586308 A JP2001586308 A JP 2001586308A JP 2004533401 A5 JP2004533401 A5 JP 2004533401A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- phosphate
- ester
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 38
- 229910019142 PO4 Inorganic materials 0.000 description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 29
- 239000010452 phosphate Substances 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 26
- 150000002148 esters Chemical class 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- 239000003814 drug Substances 0.000 description 17
- 125000002252 acyl group Chemical group 0.000 description 16
- -1 bromo, chloro, fluoro, iodo Chemical group 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000003443 antiviral agent Substances 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 150000002431 hydrogen Chemical group 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 241000711549 Hepacivirus C Species 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000005176 Hepatitis C Diseases 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000010710 hepatitis C virus infection Diseases 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 125000005354 acylalkyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000001177 diphosphate Substances 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 150000004712 monophosphates Chemical class 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- 150000003459 sulfonic acid esters Chemical class 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229910005965 SO 2 Inorganic materials 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 150000003548 thiazolidines Chemical class 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 0 *C[C@]1O[C@@](*(C=CC(*)=*2)C2=O)C(*)(*)C1* Chemical compound *C[C@]1O[C@@](*(C=CC(*)=*2)C2=O)C(*)(*)C1* 0.000 description 1
- PASOFFRBGIVJET-XGVAEZDOSA-N CC1([C@H]([n]2c(ncnc3N)c3nc2)O[C@H](CO)C1O)O Chemical compound CC1([C@H]([n]2c(ncnc3N)c3nc2)O[C@H](CO)C1O)O PASOFFRBGIVJET-XGVAEZDOSA-N 0.000 description 1
- 229940121759 Helicase inhibitor Drugs 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20658500P | 2000-05-23 | 2000-05-23 | |
| PCT/US2001/016671 WO2001090121A2 (en) | 2000-05-23 | 2001-05-23 | Methods and compositions for treating hepatitis c virus |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013036937A Division JP5926211B2 (ja) | 2000-05-23 | 2013-02-27 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2013212565A Division JP5753563B2 (ja) | 2000-05-23 | 2013-10-10 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533401A JP2004533401A (ja) | 2004-11-04 |
| JP2004533401A5 true JP2004533401A5 (enExample) | 2008-07-17 |
Family
ID=22767031
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001586308A Withdrawn JP2004533401A (ja) | 2000-05-23 | 2001-05-23 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2013036937A Expired - Lifetime JP5926211B2 (ja) | 2000-05-23 | 2013-02-27 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2013212565A Expired - Lifetime JP5753563B2 (ja) | 2000-05-23 | 2013-10-10 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2016063156A Expired - Lifetime JP6240699B2 (ja) | 2000-05-23 | 2016-03-28 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2017146982A Pending JP2018012702A (ja) | 2000-05-23 | 2017-07-28 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2018232209A Withdrawn JP2019069968A (ja) | 2000-05-23 | 2018-12-12 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013036937A Expired - Lifetime JP5926211B2 (ja) | 2000-05-23 | 2013-02-27 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2013212565A Expired - Lifetime JP5753563B2 (ja) | 2000-05-23 | 2013-10-10 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2016063156A Expired - Lifetime JP6240699B2 (ja) | 2000-05-23 | 2016-03-28 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2017146982A Pending JP2018012702A (ja) | 2000-05-23 | 2017-07-28 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
| JP2018232209A Withdrawn JP2019069968A (ja) | 2000-05-23 | 2018-12-12 | Ｃ型肝炎ウイルス治療のための方法および組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US6914054B2 (enExample) |
| EP (3) | EP1292603B8 (enExample) |
| JP (6) | JP2004533401A (enExample) |
| KR (3) | KR20080030670A (enExample) |
| CN (3) | CN101367856A (enExample) |
| AP (2) | AP2006003817A0 (enExample) |
| AR (1) | AR035336A1 (enExample) |
| AU (5) | AU7490601A (enExample) |
| BR (1) | BR0111127A (enExample) |
| CA (3) | CA2712547A1 (enExample) |
| CZ (1) | CZ301169B6 (enExample) |
| EA (2) | EA007178B1 (enExample) |
| ES (2) | ES2620807T3 (enExample) |
| IL (3) | IL152934A0 (enExample) |
| MA (1) | MA27292A1 (enExample) |
| MX (1) | MXPA02011635A (enExample) |
| MY (1) | MY164523A (enExample) |
| NO (3) | NO325352B1 (enExample) |
| NZ (2) | NZ522863A (enExample) |
| PE (2) | PE20100363A1 (enExample) |
| PL (3) | PL227118B1 (enExample) |
| RS (2) | RS53722B1 (enExample) |
| SG (5) | SG192287A1 (enExample) |
| TW (4) | TWI335334B (enExample) |
| UY (2) | UY26724A1 (enExample) |
| WO (1) | WO2001090121A2 (enExample) |
| ZA (2) | ZA200210101B (enExample) |
Families Citing this family (324)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| KR100691737B1 (ko) * | 1998-08-10 | 2007-03-12 | 이데닉스(케이만)리미티드 | Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드 |
| AU2001245575A1 (en) * | 2000-03-09 | 2001-09-17 | Videoshare, Inc. | Sharing a streaming video |
| ATE414520T1 (de) * | 2000-04-13 | 2008-12-15 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| MXPA02011691A (es) | 2000-05-26 | 2004-05-17 | Idenix Cayman Ltd | Metodos y composiciones para el tratamiento de flavivirus y pestivirus. |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| KR20040028657A (ko) | 2000-10-18 | 2004-04-03 | 파마셋, 리미티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| EP1355916B1 (en) * | 2001-01-22 | 2007-01-10 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2003000713A1 (en) * | 2001-06-21 | 2003-01-03 | Glaxo Group Limited | Nucleoside compounds in hcv |
| BR0210594A (pt) | 2001-06-22 | 2005-11-01 | Pharmasset Ltd | (beta)-d ou (beta)-l-3-halonucleosìdeo |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| AU2002353164A1 (en) * | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
| WO2003062256A1 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| WO2003062255A2 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Sugar modified nucleosides as viral replication inhibitors |
| US7217815B2 (en) | 2002-01-17 | 2007-05-15 | Valeant Pharmaceuticals North America | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents |
| CA2474563C (en) * | 2002-02-13 | 2010-11-09 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
| US20070004669A1 (en) * | 2002-06-21 | 2007-01-04 | Carroll Steven S | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2004003138A2 (en) * | 2002-06-27 | 2004-01-08 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| JP5087211B2 (ja) * | 2002-06-28 | 2012-12-05 | イデニクス（ケイマン）リミテツド | フラビウィルス感染治療のための２′および３′−ヌクレオシドプロドラッグ |
| KR20050048544A (ko) * | 2002-06-28 | 2005-05-24 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭 |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| RU2005102096A (ru) * | 2002-06-28 | 2005-11-20 | Айденикс (Кайман) Лимитед (Ky) | 2'и 3'-нуклеозидные пролекарства для лечения инфекций, вызываемых flaviviridae |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| WO2004007512A2 (en) * | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
| ES2322145T3 (es) | 2002-07-26 | 2009-06-17 | Novartis Vaccines And Diagnostics, Inc. | Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso. |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| MXPA05001298A (es) | 2002-08-01 | 2005-11-04 | Pharmasset Inc | Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae. |
| CA2499253A1 (en) * | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| WO2004041834A2 (en) * | 2002-10-31 | 2004-05-21 | Metabasis Therapeutics, Inc. | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
| US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
| ES2624353T3 (es) * | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| US7034167B2 (en) | 2002-12-06 | 2006-04-25 | Merck & Co., Inc. | Process to ribofuranose sugar derivatives as intermediates to branched-chain nucleosides |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| CN100335492C (zh) * | 2002-12-23 | 2007-09-05 | 埃迪尼克斯(开曼)有限公司 | 生产3’－核苷前体药物的方法 |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
| WO2004084453A2 (en) * | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
| CA2529311A1 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset, Inc. | Compounds for the treatment of flaviviridae infections |
| EP2359833A1 (en) | 2003-04-25 | 2011-08-24 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| EP2345658A1 (en) * | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| US7304085B2 (en) | 2003-06-04 | 2007-12-04 | Genelabs Technologies, Inc. | Nitrogen-containing heteroaryl derivatives |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| US7947817B2 (en) | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
| WO2005009418A2 (en) | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| CA2534649A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| NZ546055A (en) | 2003-08-27 | 2010-05-28 | Biota Scient Management | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| GEP20084545B (en) * | 2003-09-05 | 2008-11-25 | Anadys Pharmaceuticals Inc | Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection |
| AU2004274021B2 (en) * | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| US7642235B2 (en) | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| PL1670448T3 (pl) * | 2003-09-30 | 2008-04-30 | Tibotec Pharm Ltd | Sulfonamidy inhibitujące HCV |
| RS20060259A (sr) | 2003-10-14 | 2008-08-07 | Intermune Inc., | Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv |
| US7144868B2 (en) | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| NZ546201A (en) | 2003-10-27 | 2009-05-31 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
| US7169918B2 (en) | 2003-10-27 | 2007-01-30 | Genelabs Technologies, Inc. | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
| US7202223B2 (en) | 2003-10-27 | 2007-04-10 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| WO2005042556A1 (en) | 2003-10-27 | 2005-05-12 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| WO2005070955A1 (en) | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| EP1718608B1 (en) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
| JP5055564B2 (ja) | 2004-06-15 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのｃ−プリンヌクレオシド類似体 |
| CA2571675A1 (en) * | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| AU2005267421B2 (en) * | 2004-06-24 | 2010-06-03 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| US7745125B2 (en) | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
| CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| CA2574514A1 (en) | 2004-07-27 | 2006-10-19 | Gilead Sciences, Inc. | Phosphonate analogs of hiv inhibitor compounds |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| JP5001842B2 (ja) * | 2004-09-14 | 2012-08-15 | ギリアド ファーマセット エルエルシー | ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造 |
| WO2006121468A1 (en) | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
| WO2006093801A1 (en) | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
| CA2597683A1 (en) | 2005-02-28 | 2006-09-08 | Genelabs Technologies, Inc. | Tricyclic-nucleoside prodrugs for treating viral infections |
| US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
| CA2600886A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| KR20080016597A (ko) | 2005-05-13 | 2008-02-21 | 바이로켐 파마 인코포레이티드 | 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법 |
| KR20080033274A (ko) | 2005-06-17 | 2008-04-16 | 노파르티스 아게 | Ｈｃｖ에서 상글리페린의 용도 |
| TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| BRPI0614205A2 (pt) | 2005-08-01 | 2016-11-22 | Merck & Co Inc | composto, composição farmacêutica, e, uso de composto |
| WO2007025043A2 (en) * | 2005-08-23 | 2007-03-01 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
| GB0523041D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| MY150667A (en) | 2005-12-09 | 2014-02-28 | Gilead Pharmasset Llc | Antiviral nucleosides |
| EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| NZ569817A (en) | 2005-12-21 | 2011-10-28 | Abbott Lab | Anti-viral compounds |
| CA2633760A1 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
| WO2007075876A2 (en) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| JP2009526850A (ja) * | 2006-02-14 | 2009-07-23 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート |
| US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
| CA2647276A1 (en) * | 2006-04-04 | 2007-10-11 | F. Hoffmann-La Roche Ag | 3',5'-di-o-acylated nucleosides for hcv treatment |
| RU2448976C2 (ru) | 2006-04-11 | 2012-04-27 | Новартис Аг | Ингибиторы hcv/вич и их применение |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US8058260B2 (en) * | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| WO2008011337A1 (en) | 2006-07-19 | 2008-01-24 | Abbott Laboratories | Hcv inhibitors |
| WO2008045419A1 (en) | 2006-10-10 | 2008-04-17 | Pharmasset, Inc. | Preparation of nucleosides ribofuranosyl pyrimidines |
| NZ575889A (en) | 2006-10-10 | 2011-09-30 | Medivir Ab | Hcv nucleoside inhibitor |
| EP2079479B1 (en) | 2006-10-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US8377873B2 (en) | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| MY164469A (en) | 2006-10-27 | 2017-12-15 | Msd Italia Srl | Hcv ns3 protease inhibitors |
| CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
| KR101165936B1 (ko) | 2006-11-09 | 2012-07-19 | 에프. 호프만-라 로슈 아게 | 티아졸 및 옥사졸-치환된 아릴아마이드 |
| EP2559692A1 (en) | 2006-11-15 | 2013-02-20 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of Flavivirus infections |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| AU2007335962B2 (en) | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
| EP2120565B1 (en) * | 2006-12-20 | 2012-11-28 | Merck Sharp & Dohme Corp. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| CA2673649A1 (en) * | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2121717A4 (en) * | 2007-01-17 | 2013-05-29 | Inst Rech S Cliniques De Montreal | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES WITH QUANTUMARY CARBON CENTERS AND USE METHOD |
| ATE525068T1 (de) | 2007-02-28 | 2011-10-15 | Conatus Pharmaceuticals Inc | Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| EP2178886A1 (en) | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| JP5433573B2 (ja) | 2007-07-19 | 2014-03-05 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 抗ウイルス剤としての大環状化合物 |
| DK2203430T3 (da) * | 2007-09-17 | 2011-09-26 | Abbott Lab | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) |
| SG183733A1 (en) * | 2007-09-17 | 2012-09-27 | Abbott Lab | Uracil or thymine derivative for treating hepatitis c |
| EP2203431B1 (en) | 2007-09-17 | 2011-08-10 | Abbott Laboratories | Anti-infective pyrimidines and uses thereof |
| CN103214464B (zh) | 2007-12-17 | 2015-02-18 | 霍夫曼-拉罗奇有限公司 | 四唑取代的芳基酰胺衍生物和它们作为p2x3和/或p2x2/3嘌呤能受体拮抗物的用途 |
| CA2708791C (en) | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Imidazole-substituted arylamides and uses thereof as p2x receptor antagonists |
| ES2541662T3 (es) | 2007-12-17 | 2015-07-23 | F. Hoffmann-La Roche Ag | Derivados arilamida sustituidos con triazol y utilización de los mismos como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3 |
| HRP20130614T1 (en) | 2007-12-17 | 2013-08-31 | F. Hoffmann - La Roche Ag | Novel pyrazole-substituted arylamides |
| US8227431B2 (en) * | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
| US8846636B2 (en) | 2008-03-18 | 2014-09-30 | Lcb Pharma Inc. | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use |
| TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| DK2268642T3 (en) | 2008-04-23 | 2015-05-26 | Gilead Sciences Inc | 1'-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
| JP2011518882A (ja) | 2008-04-28 | 2011-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｃｖｎｓ３プロテアーゼ阻害剤 |
| WO2009150405A1 (en) | 2008-06-09 | 2009-12-17 | Cyclacel Limited | Combination of spacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EP2476690A1 (en) * | 2008-07-02 | 2012-07-18 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| NZ590075A (en) * | 2008-07-08 | 2012-12-21 | Gilead Sciences Inc | citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate |
| UA100436C2 (en) | 2008-07-22 | 2012-12-25 | Mepk Шарп Энд Доме Корп. | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
| EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| US8759318B2 (en) * | 2009-01-09 | 2014-06-24 | Inhibitex, Inc. | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
| WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
| GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| BRPI1005401A2 (pt) | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
| WO2010093608A1 (en) | 2009-02-10 | 2010-08-19 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
| WO2010107739A2 (en) | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a flaviviridae family viral infection |
| BRPI1009324A2 (pt) * | 2009-03-20 | 2015-11-24 | Alios Biopharma Inc | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| JP5639155B2 (ja) | 2009-05-13 | 2014-12-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルスインヒビターとしての大環状化合物 |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
| WO2010149634A1 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists |
| CN102574778B (zh) | 2009-06-22 | 2015-01-07 | 弗·哈夫曼-拉罗切有限公司 | 新的联苯基和苯基-吡啶酰胺类化合物 |
| WO2010149541A1 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel oxazolone and pyrrolidinone-substituted arylamides |
| EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
| JP2013501068A (ja) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
| CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| EP2480552B1 (en) | 2009-09-21 | 2016-11-09 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| CA2780044A1 (en) | 2009-11-14 | 2011-05-19 | F. Hoffmann-La Roche Ag | Biomarkers for predicting rapid response to hcv treatment |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| AU2010326225A1 (en) | 2009-11-25 | 2012-06-07 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| CN102656459A (zh) | 2009-12-02 | 2012-09-05 | 弗·哈夫曼-拉罗切有限公司 | 用于预测对hcv治疗持续应答的生物标志物 |
| MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
| CA2784036A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| WO2011119674A1 (en) * | 2010-03-23 | 2011-09-29 | University Of Utah Research Foundation | Methods and compositions related to modified adenosines for controlling off-target effects in rna interference |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| TW201141857A (en) | 2010-03-24 | 2011-12-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
| WO2011119858A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| AU2011232348A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
| TWI498117B (zh) | 2010-03-31 | 2015-09-01 | Gilead Pharmasset Llc | 核苷氨基磷酸酯 |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| EP2582717A2 (en) | 2010-06-15 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Hcv ns5b polymerase mutants |
| AR081691A1 (es) | 2010-06-28 | 2012-10-10 | Vertex Pharma | Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus |
| WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| EP2585448A1 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| EP3415504A1 (en) | 2010-07-16 | 2018-12-19 | AbbVie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| KR101774742B1 (ko) | 2010-07-16 | 2017-09-11 | 애브비 아일랜드 언리미티드 컴퍼니 | 촉매 반응용 포스핀 리간드 |
| US9090642B2 (en) | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SI2595980T1 (sl) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij |
| CA2808291A1 (en) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| AU2011306066B2 (en) | 2010-09-20 | 2015-01-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| KR102163902B1 (ko) | 2010-09-21 | 2020-10-12 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제 |
| PE20171640A1 (es) | 2010-09-22 | 2017-11-09 | Alios Biopharma Inc | Analogos de nucleotidos sustituidos |
| EP2624826B1 (en) | 2010-10-08 | 2018-07-18 | Novartis AG | Vitamin e formulations of sulfamide ns3 inhibitors |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
| WO2012092484A2 (en) * | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| JP2014511875A (ja) * | 2011-04-13 | 2014-05-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法 |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013026345A2 (pt) * | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| BR112013026219A2 (pt) | 2011-04-13 | 2016-07-26 | Gilead Sciences Inc | análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral |
| US10226478B2 (en) | 2011-04-14 | 2019-03-12 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| CN102775458B (zh) * | 2011-05-09 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 |
| CA2836579A1 (en) * | 2011-05-19 | 2012-11-22 | Rfs Pharma, Llc | Purine monophosphate prodrugs for treatment of viral infections |
| WO2013009735A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP2731433A4 (en) | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
| WO2013016492A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| US8951985B2 (en) | 2011-09-12 | 2015-02-10 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN107898790B (zh) | 2011-11-30 | 2024-06-21 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
| MY171759A (en) | 2011-12-06 | 2019-10-28 | Univ Leland Stanford Junior | Methods and compositions for treating viral diseases |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
| WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
| WO2013123138A2 (en) | 2012-02-14 | 2013-08-22 | University Of Georgia Research Foundation, Inc. | Spiro [2.4]heptanes for treatment of flaviviridae infections |
| CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| US20130315868A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| WO2014033617A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| WO2014049540A2 (en) | 2012-09-29 | 2014-04-03 | Novartis Ag | Cyclic peptides and use as medicines |
| CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
| WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
| US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| EP2935303B1 (en) | 2012-12-21 | 2021-02-17 | Janssen BioPharma, Inc. | 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| RU2015148010A (ru) | 2013-04-12 | 2017-05-15 | Ачиллион Фармасютикалз, Инк. | Высокоактивное производное нуклеозида для лечения hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| US9326983B2 (en) | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| US10149859B2 (en) * | 2013-09-11 | 2018-12-11 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
| CN104211748B (zh) * | 2013-11-15 | 2017-05-31 | 南京济群医药科技股份有限公司 | 6‑羟基双脱氧鸟嘌呤核苷磷酸酯制备和用途 |
| US20170198005A1 (en) | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| EP3083654A1 (en) | 2013-12-18 | 2016-10-26 | Idenix Pharmaceuticals LLC | 4'-or nucleosides for the treatment of hcv |
| WO2015123352A1 (en) | 2014-02-13 | 2015-08-20 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| US20170066795A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
| US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| EP3131914B1 (en) * | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| CN107428792B (zh) | 2014-12-15 | 2023-01-24 | 埃默里大学 | 用于治疗乙型肝炎病毒的磷酰胺 |
| PL3261644T3 (pl) | 2015-02-26 | 2021-10-25 | University Of Kentucky Research Foundation | Kompozycje i sposoby leczenia degradacji siatkówki |
| US11219623B2 (en) | 2015-02-26 | 2022-01-11 | University Of Kentucky Research Foundation | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| SI3349758T1 (sl) | 2015-09-16 | 2022-08-31 | Gilead Sciences, Inc. | Postopki za zdravljenje okužb z virusom arenaviridae |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| BR112018076913A2 (pt) | 2016-06-24 | 2019-04-02 | Emory University | fosforamidatos para o tratamento do vírus da hepatite b |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| CN109689672B (zh) | 2016-09-07 | 2023-05-30 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
| GEP20227457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
| KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US11066923B2 (en) | 2017-06-26 | 2021-07-20 | Hrl Laboratories, Llc | System and method for generating output of a downhole inertial measurement unit |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| AU2019360210B2 (en) * | 2018-10-17 | 2025-07-10 | Xibin Liao | 6-Mercaptopurine nucleoside analogues |
| JP7584418B2 (ja) | 2018-12-04 | 2024-11-15 | ブリストル－マイヤーズ スクイブ カンパニー | 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法 |
| CN112898292A (zh) | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| CN114641299A (zh) | 2020-01-27 | 2022-06-17 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN118994170A (zh) | 2020-03-12 | 2024-11-22 | 吉利德科学公司 | 制备1'-氰基核苷的方法 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| EP4157272B1 (en) | 2020-05-29 | 2025-07-02 | Gilead Sciences, Inc. | Remdesivir for the treatment of viral infections |
| US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
| WO2022008025A1 (en) * | 2020-07-05 | 2022-01-13 | Since & Technology Development Fund Authority | 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto |
| CA3188373A1 (en) | 2020-08-24 | 2022-03-03 | Scott E. Lazerwith | Phospholipid compounds and uses thereof |
| SI4204421T1 (sl) | 2020-08-27 | 2024-07-31 | Gilead Sciences, Inc., | Spojine in postopki za zdravljenje virusnih okužb |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| KR20240022574A (ko) | 2021-06-17 | 2024-02-20 | 아테아 파마슈티컬즈, 인크. | 유리한 항-hcv 조합 요법 |
| EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (384)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE140254C (enExample) | ||||
| US147160A (en) * | 1874-02-03 | Improvement in seed-planters | ||
| US55483A (en) * | 1866-06-12 | Improvement in pruning-hooks | ||
| US83307A (en) * | 1868-10-20 | Improvement in wash-boilehs | ||
| US87873A (en) * | 1869-03-16 | Perry prettyman | ||
| US28013A (en) * | 1860-04-24 | Improved bullet-ladle | ||
| US19363A (en) * | 1858-02-16 | Improved harpoon-and lance | ||
| US50229A (en) * | 1865-10-03 | Improvement in cultivators | ||
| US8841A (en) * | 1852-03-30 | Sice-httxieb | ||
| US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
| US3074929A (en) | 1955-08-11 | 1963-01-22 | Burroughs Wellcome Co | Glycosides of 6-mercaptopurine |
| GB924246A (en) | 1958-12-23 | 1963-04-24 | Wellcome Found | Purine derivatives and their preparation |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| GB984877A (en) | 1962-08-16 | 1965-03-03 | Waldhof Zellstoff Fab | Improvements in and relating to 6-halonucleosides |
| GB1163103A (en) * | 1965-11-15 | 1969-09-04 | Merck & Co Inc | Ribofuranosyl Purine Derivatives |
| FR1498856A (enExample) | 1965-11-15 | 1968-01-10 | ||
| DE1695411A1 (de) | 1966-05-02 | 1971-04-15 | Merck & Co Inc | Substituierte Purin-Nucleoside und Verfahren zu deren Herstellung |
| FR1521076A (fr) * | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Nucléosides de purines substituées |
| US3480613A (en) * | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
| JPS4621872Y1 (enExample) | 1968-02-27 | 1971-07-28 | ||
| DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
| US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| JPS4848495A (enExample) | 1971-09-21 | 1973-07-09 | ||
| US4022889A (en) | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
| DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| US4058602A (en) | 1976-08-09 | 1977-11-15 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine |
| DE2757365A1 (de) * | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| DE2852721A1 (de) | 1978-12-06 | 1980-06-26 | Basf Ag | Verfahren zur reindarstellung von kaliumribonat und ribonolacton |
| US4239753A (en) | 1978-12-12 | 1980-12-16 | The Upjohn Company | Composition of matter and process |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2562543B1 (fr) | 1984-04-10 | 1987-09-25 | Elf Aquitaine | Nouveaux phosphonites cycliques, leur preparation et applications |
| NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| KR880000094B1 (ko) | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
| JPS61204193A (ja) | 1985-03-05 | 1986-09-10 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| JPS61212592A (ja) | 1985-03-19 | 1986-09-20 | Tokyo Tanabe Co Ltd | Ｄ−リボ−スの製造方法 |
| US4605659A (en) * | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
| JPS61263995A (ja) | 1985-05-16 | 1986-11-21 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
| US4754026A (en) * | 1985-06-04 | 1988-06-28 | Takeda Chemical Industries, Ltd. | Conversion of uracil derivatives to cytosine derivatives |
| US5455339A (en) | 1986-05-01 | 1995-10-03 | University Of Georgia Research Foundation, Inc. | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides |
| JPH0699467B2 (ja) | 1987-03-04 | 1994-12-07 | ヤマサ醤油株式会社 | ２▲’▼−デオキシ−２▲’▼（ｓ）−アルキルピリミジンヌクレオシド誘導体 |
| DE3714473A1 (de) | 1987-04-30 | 1988-11-10 | Basf Ag | Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose |
| GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
| WO1989002733A1 (en) | 1987-09-22 | 1989-04-06 | The Regents Of The University Of California | Liposomal nucleoside analogues for treating aids |
| US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
| US5122517A (en) * | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
| NZ229453A (en) | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
| US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
| US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
| US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
| US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5118672A (en) | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
| US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| US6060592A (en) * | 1990-01-11 | 2000-05-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same |
| US5200514A (en) * | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5969109A (en) | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
| EP1304335B1 (en) | 1990-04-04 | 2009-06-10 | Novartis Vaccines and Diagnostics, Inc. | Hepatitis C virus protease |
| ATE194844T1 (de) | 1990-04-06 | 2000-08-15 | Genelabs Tech Inc | Hepatitis c-virus-epitope |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| FR2662165B1 (fr) * | 1990-05-18 | 1992-09-11 | Univ Paris Curie | Derives nucleosidiques branches, leur procede de preparation et leur utilisation a titre de medicament. |
| JPH05507279A (ja) | 1990-05-29 | 1993-10-21 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | グリセロールジ―およびトリホスフェート誘導体の合成 |
| CA2083961A1 (en) * | 1990-05-29 | 1991-11-30 | Henk Van Den Bosch | Synthesis of glycerol di- and triphosphate derivatives |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| JPH04266880A (ja) | 1991-02-22 | 1992-09-22 | Japan Tobacco Inc | ３ −ｄｐａ− ラクトンの製造方法 |
| DE69233693T2 (de) | 1991-03-06 | 2008-01-24 | Emory University | Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| AU668873B2 (en) | 1991-07-12 | 1996-05-23 | Chimerix, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| JPH0525152A (ja) * | 1991-07-22 | 1993-02-02 | Japan Tobacco Inc | ３−ｄｐａ−ラクトンの製造法 |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| TW224053B (enExample) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| ZA931934B (en) | 1992-03-18 | 1993-03-18 | Us Bioscience | Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
| US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| US5401861A (en) * | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
| US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
| US5256797A (en) | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
| US5606048A (en) * | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| AU4508493A (en) * | 1992-07-02 | 1994-01-31 | Wellcome Foundation Limited, The | Therapeutic nucleosides |
| DE4224737A1 (de) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung |
| CA2105112C (en) | 1992-09-01 | 2005-08-02 | Thomas C. Britton | A process for anomerizing nucleosides |
| US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| AU680435B2 (en) | 1992-09-10 | 1997-07-31 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US5922857A (en) | 1992-09-28 | 1999-07-13 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
| JPH06135988A (ja) | 1992-10-22 | 1994-05-17 | Toagosei Chem Ind Co Ltd | ヌクレオシド誘導体 |
| GB9226729D0 (en) | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
| JPH06211890A (ja) | 1993-01-12 | 1994-08-02 | Yamasa Shoyu Co Ltd | ２’−デオキシ−２’（ｓ）−置換アルキルシチジン誘導体 |
| JPH06228186A (ja) | 1993-01-29 | 1994-08-16 | Yamasa Shoyu Co Ltd | ２’−デオキシ−（２’ｓ）−アルキルピリミジンヌクレオシド誘導体 |
| WO1994019012A2 (en) | 1993-02-24 | 1994-09-01 | Wang Jui H | Compositions and methods of application of reactive antiviral polymers |
| CA2159639A1 (en) | 1993-04-02 | 1994-10-13 | Vincent J. Miles | Method for selective inactivation of viral replication |
| GB9307043D0 (en) | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| JP3693357B2 (ja) | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
| AU701574B2 (en) | 1993-05-12 | 1999-02-04 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
| ATE226437T1 (de) | 1993-06-10 | 2002-11-15 | Univ Wake Forest | (phospho)lipide zum bekämpfen einer hepatitis b- infektion |
| CA2167537A1 (en) | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| DE4415539C2 (de) | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Pflanzen mit virustatischer und antiviraler Wirkung |
| EP0759979A4 (en) | 1994-05-10 | 1999-10-20 | Gen Hospital Corp | THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS |
| DE4432623A1 (de) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Verfahren zur Bleichung von wäßrigen Tensidlösungen |
| US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| EP0747389B1 (en) | 1994-12-13 | 2003-09-10 | Taiho Pharmaceutical Co., Ltd. | 3'-substituted nucleoside derivatives |
| GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| DE19513330A1 (de) * | 1995-04-03 | 1996-10-10 | Schering Ag | Neues Verfahren zur Herstellung von Nucleosiden |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US5861267A (en) | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
| DE19531226C1 (de) | 1995-08-24 | 1997-04-03 | Immuno Ag | Pharmazeutische Zusammensetzungen, enthaltend ein neutralisiertes Virus, und Verwendung derselben |
| JPH0959292A (ja) | 1995-08-25 | 1997-03-04 | Yamasa Shoyu Co Ltd | ４−アミノピリミジンヌクレオシドの製造法 |
| JPH11512397A (ja) | 1995-09-07 | 1999-10-26 | ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド | 治療用アジド化合物 |
| WO1997012033A1 (en) | 1995-09-27 | 1997-04-03 | Emory University | Recombinant hepatitis c virus rna replicase |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
| AU2064297A (en) | 1996-02-29 | 1997-09-16 | Immusol, Inc | Hepatitis c virus ribozymes |
| US5759795A (en) | 1996-03-08 | 1998-06-02 | Schering Corporation | Assay for determining inhibitors of ATPase |
| US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
| GB9609932D0 (en) | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
| US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| IL129126A0 (en) * | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| KR100386140B1 (ko) * | 1996-10-16 | 2003-06-02 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도 |
| DK0932617T3 (da) | 1996-10-18 | 2002-04-22 | Vertex Pharma | Inhibitorer af serinproteaser, især af hepatitis C-virus-NS3-protease |
| US6063628A (en) | 1996-10-28 | 2000-05-16 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| IL119833A (en) | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
| US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| YU61598A (sh) | 1997-01-17 | 2003-02-28 | Icn Pharmaceuticals Inc. | Tretmani bolesti uz korišćenje citokina |
| US6030785A (en) | 1997-03-05 | 2000-02-29 | University Of Washington | Screening methods to identify agents that selectively inhibit hepatitis C virus replication |
| AU739240B2 (en) | 1997-03-19 | 2001-10-04 | Emory University | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides |
| US5849800A (en) | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
| US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| DE69814878T2 (de) | 1997-06-30 | 2004-05-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane als nmda-rezeptor-antagonisten |
| US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| ATE206618T1 (de) | 1997-09-21 | 2001-10-15 | Schering Corp | Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion |
| DK1027365T3 (da) | 1997-10-30 | 2005-05-30 | Us Gov Health & Human Serv | Antitumor-uridinanaloger |
| WO1999043691A1 (en) * | 1998-02-25 | 1999-09-02 | Emory University | 2'-fluoronucleosides |
| KR100389853B1 (ko) | 1998-03-06 | 2003-08-19 | 삼성전자주식회사 | 카타로그정보의기록및재생방법 |
| ES2401070T3 (es) | 1998-03-06 | 2013-04-16 | Metabasis Therapeutics, Inc. | Nuevos profármacos para compuestos que contienen fósforo |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
| BR9910505A (pt) | 1998-05-15 | 2001-01-02 | Schering Corp | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| EP1087778B1 (en) * | 1998-06-08 | 2005-10-26 | F. Hoffmann-La Roche Ag | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| KR100691737B1 (ko) | 1998-08-10 | 2007-03-12 | 이데닉스(케이만)리미티드 | Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드 |
| CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
| US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6458773B1 (en) | 1998-11-05 | 2002-10-01 | Emory University | Nucleoside with anti-hepatitis B virus activity |
| BR9915037A (pt) | 1998-11-05 | 2001-11-20 | Uab Research Foundation | Nucleosìdeos ß-l-2'-deoxi para o tratamento deinfecção de hiv |
| WO2000037110A2 (en) | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| EP1155017B1 (en) | 1999-02-22 | 2003-01-15 | Shire Biochem Inc. | [1,8] naphthyridine derivatives having antiviral activity |
| HUP0200260A3 (en) | 1999-03-05 | 2002-11-28 | Metabasis Therapeutics Inc San | Novel phosphorus-containing prodrugs, their preparation and their use |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| WO2001018013A1 (en) | 1999-09-08 | 2001-03-15 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
| CA2389745C (en) * | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| EP1240174A2 (en) | 1999-12-22 | 2002-09-18 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| AU2338101A (en) | 1999-12-30 | 2001-07-16 | Biochem Pharma Inc. | Imidazopyrimidine nucleoside analogues with anti-hiv activity |
| US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| US7056895B2 (en) | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| CN1427722A (zh) | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
| ATE414520T1 (de) | 2000-04-13 | 2008-12-15 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
| GB0009486D0 (en) | 2000-04-17 | 2000-06-07 | Univ Cardiff | Chemical compounds |
| WO2001081359A1 (en) | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| GB0011203D0 (en) | 2000-05-09 | 2000-06-28 | Univ Cardiff | Chemical compounds |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| MXPA02011691A (es) * | 2000-05-26 | 2004-05-17 | Idenix Cayman Ltd | Metodos y composiciones para el tratamiento de flavivirus y pestivirus. |
| BR0111195A (pt) | 2000-05-26 | 2004-07-20 | Idenix Cayman Ltd | Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta |
| US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| CA2421040C (en) | 2000-09-01 | 2010-01-12 | Ribozyme Pharmaceuticals, Incorporated | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
| CN1516599A (zh) | 2000-10-18 | 2004-07-28 | ���鹫˾ | 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法 |
| EP1360325A2 (en) | 2000-10-18 | 2003-11-12 | Pharmasset Limited | Multiplex quantification of nucleic acids in diseased cells |
| KR20040028657A (ko) | 2000-10-18 | 2004-04-03 | 파마셋, 리미티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| JP2005502580A (ja) | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | フラビウィルス感染治療用抗ウィルス薬 |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| EP1355916B1 (en) | 2001-01-22 | 2007-01-10 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| AU2002255654B2 (en) | 2001-03-01 | 2008-05-15 | Pharmasset, Inc. | Method for the synthesis of 2',3'-dideoxy -2',3'-didehydronucleosides |
| GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| BR0210594A (pt) | 2001-06-22 | 2005-11-01 | Pharmasset Ltd | (beta)-d ou (beta)-l-3-halonucleosìdeo |
| ATE555102T1 (de) * | 2001-07-16 | 2012-05-15 | Genzyme Corp | N-acylsphingosinglucosyltransferase-inhibitor |
| DE10137252A1 (de) * | 2001-07-31 | 2003-02-13 | Voith Paper Patent Gmbh | Verfahren zum Aufwickeln einer laufenden Materialbahn sowie Wickelmaschine zur Durchführung des Verfahrens |
| TWI239270B (en) * | 2001-08-02 | 2005-09-11 | Primax Electronics Ltd | Shredder which can shred small object |
| WO2003024461A1 (en) | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| WO2003063771A2 (en) | 2001-12-14 | 2003-08-07 | Pharmasset Ltd. | N4-acylcytosine nucleosides for treatment of viral iinfections |
| AU2002353165A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
| WO2003062255A2 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Sugar modified nucleosides as viral replication inhibitors |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| CA2474563C (en) | 2002-02-13 | 2010-11-09 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
| AU2003217402A1 (en) | 2002-02-14 | 2003-09-04 | Pharmasset Inc | Modified fluorinated nucleoside analogues |
| EP1485395A4 (en) | 2002-02-28 | 2011-04-13 | Biota Scient Management | NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF |
| WO2003081899A1 (en) | 2002-03-18 | 2003-10-02 | Massachusetts Institute Of Technology | Event-driven charge-coupled device design and applications therefor |
| US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| KR20050006221A (ko) | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
| WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| US20040014108A1 (en) | 2002-05-24 | 2004-01-22 | Eldrup Anne B. | Oligonucleotides having modified nucleoside units |
| DE10226932A1 (de) | 2002-06-17 | 2003-12-24 | Bayer Ag | Strahlenhärtende Beschichtungsmittel |
| EP1515971A2 (en) | 2002-06-17 | 2005-03-23 | Merck & Co., Inc. | Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US20070004669A1 (en) | 2002-06-21 | 2007-01-04 | Carroll Steven S | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2004003138A2 (en) | 2002-06-27 | 2004-01-08 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| KR20050048544A (ko) | 2002-06-28 | 2005-05-24 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭 |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| MXPA04012802A (es) * | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| JP5087211B2 (ja) | 2002-06-28 | 2012-12-05 | イデニクス（ケイマン）リミテツド | フラビウィルス感染治療のための２′および３′−ヌクレオシドプロドラッグ |
| WO2004007512A2 (en) | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
| US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| WO2004023921A1 (en) | 2002-09-16 | 2004-03-25 | Kyeong Ho Kim | Decoration band |
| US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| CA2499253A1 (en) | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
| CA2504554A1 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | 2'-substituted oligomeric compounds and compositions for use in gene modulations |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| CN100335492C (zh) | 2002-12-23 | 2007-09-05 | 埃迪尼克斯(开曼)有限公司 | 生产3’－核苷前体药物的方法 |
| US7799908B2 (en) | 2003-01-15 | 2010-09-21 | Valeant Pharmaceuticals North America | Synthesis and use of 2′-substituted-N6 -modified nucleosides |
| AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
| WO2004080466A1 (en) | 2003-03-07 | 2004-09-23 | Ribapharm Inc. | Cytidine analogs and methods of use |
| WO2004084453A2 (en) | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
| CA2529311A1 (en) | 2003-03-28 | 2004-10-07 | Pharmasset, Inc. | Compounds for the treatment of flaviviridae infections |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| EP2359833A1 (en) | 2003-04-25 | 2011-08-24 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| KR20060015542A (ko) | 2003-04-28 | 2006-02-17 | 이데닉스 (케이만) 리미티드 | 산업 규모의 뉴클레오시드 합성 |
| US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| EP1656093A2 (en) | 2003-05-14 | 2006-05-17 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| MXPA05013452A (es) | 2003-06-19 | 2006-03-09 | Hoffmann La Roche | Proceso para preparar derivados de 4'-azidonucleosido. |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| NZ546055A (en) | 2003-08-27 | 2010-05-28 | Biota Scient Management | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| CA2539914A1 (en) | 2003-09-22 | 2005-04-07 | Acidophil Llc | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| US7144868B2 (en) | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| NZ546201A (en) * | 2003-10-27 | 2009-05-31 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
| WO2005042556A1 (en) | 2003-10-27 | 2005-05-12 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
| WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| JP5055564B2 (ja) | 2004-06-15 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのｃ−プリンヌクレオシド類似体 |
| WO2006002231A1 (en) | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| CA2571675A1 (en) | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| AU2005267421B2 (en) | 2004-06-24 | 2010-06-03 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| MX2007000803A (es) | 2004-07-21 | 2007-04-02 | Pharmasset Inc | Preparacion de 2-desoxi-2-fluoro-d-ribofuranosil pirimidinas y purinas alquil-sustituidas y sus derivados. |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| CA2574514A1 (en) | 2004-07-27 | 2006-10-19 | Gilead Sciences, Inc. | Phosphonate analogs of hiv inhibitor compounds |
| DE602005015466D1 (de) * | 2004-08-23 | 2009-08-27 | Hoffmann La Roche | Antivirale 4'-azidonucleoside |
| RU2007115419A (ru) | 2004-09-24 | 2008-10-27 | Айденикс (Кайман) Лимитед (Ky) | Способы и композиции для лечения флавивирусов, пестивирусов и гепацивируса |
| EA200700718A1 (ru) | 2004-10-06 | 2007-12-28 | Мидженикс Инк. | Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения |
| JP2008517912A (ja) * | 2004-10-21 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | ＲＮＡ依存性ＲＮＡウイルス感染治療用フッ素化ピロロ［２，３−ｄ］ピリミジンヌクレオシド |
| WO2006121468A1 (en) | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
| JP2008523082A (ja) | 2004-12-09 | 2008-07-03 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗菌活性および抗癌活性を有するヌクレオチド |
| WO2006063717A2 (en) | 2004-12-16 | 2006-06-22 | Febit Biotech Gmbh | Polymerase-independent analysis of the sequence of polynucleotides |
| JP2008530124A (ja) | 2005-02-09 | 2008-08-07 | ミジェニックス インコーポレイテッド | フラビウイルス感染症を処置または予防するための組成物および方法 |
| JP2008535932A (ja) | 2005-03-09 | 2008-09-04 | イデニクス（ケイマン）リミテツド | 抗ウィルス剤としての非天然塩基を有するヌクレオシド |
| US8163744B2 (en) | 2005-03-18 | 2012-04-24 | Nexuspharma, Inc. | Tetrahydro-isoquinolin-1-ones for the treatment of cancer |
| DE102005012681A1 (de) | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
| GT200600119A (es) | 2005-03-24 | 2006-10-25 | Composiciones farmaceuticas | |
| AR056327A1 (es) | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| AU2006252718B2 (en) | 2005-05-31 | 2010-04-15 | Novartis Ag | Treatment of liver diseases in which iron plays a role in pathogenesis |
| US20100017895A1 (en) | 2005-07-18 | 2010-01-21 | Amy Weiner | Small animal model for hcv replication |
| US7632821B2 (en) | 2005-08-09 | 2009-12-15 | Merck & Co., Inc. | Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection |
| BRPI0615157A2 (pt) | 2005-08-12 | 2016-09-13 | Merck & Co Inc | composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto |
| AR057096A1 (es) | 2005-08-26 | 2007-11-14 | Chancellors Masters And Schola | Proceso para preparar acidos y lactonas sacarinicos |
| CA2623522C (en) | 2005-09-26 | 2015-12-08 | Pharmasset, Inc. | Modified 4'-nucleosides as antiviral agents |
| MY150667A (en) | 2005-12-09 | 2014-02-28 | Gilead Pharmasset Llc | Antiviral nucleosides |
| WO2007075876A2 (en) | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| JP2009526850A (ja) | 2006-02-14 | 2009-07-23 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート |
| WO2008005542A2 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
| WO2008045419A1 (en) | 2006-10-10 | 2008-04-17 | Pharmasset, Inc. | Preparation of nucleosides ribofuranosyl pyrimidines |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| EP2120565B1 (en) | 2006-12-20 | 2012-11-28 | Merck Sharp & Dohme Corp. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| CA2685748A1 (en) | 2007-05-14 | 2008-11-14 | Rfs Pharma, Llc. | Azido purine nucleosides for treatment of viral infections |
| GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| DK2268642T3 (en) | 2008-04-23 | 2015-05-26 | Gilead Sciences Inc | 1'-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| BRPI1005401A2 (pt) | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
| WO2010093608A1 (en) | 2009-02-10 | 2010-08-19 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| KR101961601B1 (ko) | 2009-11-16 | 2019-03-25 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법 |
| TWI498117B (zh) | 2010-03-31 | 2015-09-01 | Gilead Pharmasset Llc | 核苷氨基磷酸酯 |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| WO2011156757A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
| US9090642B2 (en) | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US20130273005A1 (en) | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
| WO2012092484A2 (en) | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| BR112013026219A2 (pt) | 2011-04-13 | 2016-07-26 | Gilead Sciences Inc | análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| JP2014511875A (ja) | 2011-04-13 | 2014-05-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法 |
| CA2836579A1 (en) | 2011-05-19 | 2012-11-22 | Rfs Pharma, Llc | Purine monophosphate prodrugs for treatment of viral infections |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| US8951985B2 (en) * | 2011-09-12 | 2015-02-10 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8575119B2 (en) | 2011-09-23 | 2013-11-05 | Enanta Pharmaceuticals, Inc. | 2′-chloroacetylenyl substituted nucleoside derivatives |
| EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| US20130315868A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
| US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
| US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
| US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| WO2014137926A1 (en) * | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2014204831A1 (en) | 2013-06-18 | 2014-12-24 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
-
2001
- 2001-05-22 MY MYPI20012400A patent/MY164523A/en unknown
- 2001-05-23 BR BR0111127-2A patent/BR0111127A/pt not_active Application Discontinuation
- 2001-05-23 CN CNA2008101081373A patent/CN101367856A/zh active Pending
- 2001-05-23 TW TW098105775A patent/TWI335334B/zh not_active IP Right Cessation
- 2001-05-23 PL PL389775A patent/PL227118B1/pl unknown
- 2001-05-23 IL IL15293401A patent/IL152934A0/xx unknown
- 2001-05-23 SG SG2010004232A patent/SG192287A1/en unknown
- 2001-05-23 KR KR1020087003747A patent/KR20080030670A/ko not_active Ceased
- 2001-05-23 PL PL409123A patent/PL409123A1/pl unknown
- 2001-05-23 PE PE2010000216A patent/PE20100363A1/es not_active Application Discontinuation
- 2001-05-23 AP AP2006003817A patent/AP2006003817A0/xx unknown
- 2001-05-23 PE PE2001000470A patent/PE20020206A1/es not_active Application Discontinuation
- 2001-05-23 CN CNB018132332A patent/CN100402545C/zh not_active Expired - Lifetime
- 2001-05-23 UY UY26724A patent/UY26724A1/es not_active IP Right Cessation
- 2001-05-23 AP APAP/P/2002/002704A patent/AP1782A/en active
- 2001-05-23 EP EP01941564.5A patent/EP1292603B8/en not_active Expired - Lifetime
- 2001-05-23 NZ NZ522863A patent/NZ522863A/en not_active IP Right Cessation
- 2001-05-23 EP EP10183341.6A patent/EP2319856B1/en not_active Expired - Lifetime
- 2001-05-23 RS RS20120201A patent/RS53722B1/sr unknown
- 2001-05-23 JP JP2001586308A patent/JP2004533401A/ja not_active Withdrawn
- 2001-05-23 CA CA2712547A patent/CA2712547A1/en not_active Abandoned
- 2001-05-23 KR KR1020077006401A patent/KR20070036806A/ko not_active Ceased
- 2001-05-23 MX MXPA02011635A patent/MXPA02011635A/es active IP Right Grant
- 2001-05-23 TW TW094131057A patent/TWI331528B/zh not_active IP Right Cessation
- 2001-05-23 EA EA200201279A patent/EA007178B1/ru not_active IP Right Cessation
- 2001-05-23 TW TW096112264A patent/TW200730537A/zh unknown
- 2001-05-23 ES ES01941564.5T patent/ES2620807T3/es not_active Expired - Lifetime
- 2001-05-23 SG SG10201710373RA patent/SG10201710373RA/en unknown
- 2001-05-23 PL PL366159A patent/PL220775B1/pl not_active IP Right Cessation
- 2001-05-23 CA CA2910995A patent/CA2910995C/en not_active Expired - Lifetime
- 2001-05-23 US US09/864,078 patent/US6914054B2/en not_active Expired - Lifetime
- 2001-05-23 CZ CZ20024149A patent/CZ301169B6/cs not_active IP Right Cessation
- 2001-05-23 EA EA200600582A patent/EA011720B1/ru not_active IP Right Cessation
- 2001-05-23 TW TW090112342A patent/TWI317735B/zh not_active IP Right Cessation
- 2001-05-23 CN CNA2008101081405A patent/CN101469009A/zh active Pending
- 2001-05-23 EP EP06075216A patent/EP1669364A3/en not_active Withdrawn
- 2001-05-23 CA CA2409613A patent/CA2409613C/en not_active Expired - Lifetime
- 2001-05-23 RS YU92102A patent/RS52394B/sr unknown
- 2001-05-23 NZ NZ540755A patent/NZ540755A/en not_active IP Right Cessation
- 2001-05-23 KR KR1020027015790A patent/KR20030036188A/ko not_active Ceased
- 2001-05-23 ES ES10183341T patent/ES2531011T3/es not_active Expired - Lifetime
- 2001-05-23 WO PCT/US2001/016671 patent/WO2001090121A2/en not_active Ceased
- 2001-05-23 SG SG200407754-1A patent/SG156517A1/en unknown
- 2001-05-23 AU AU7490601A patent/AU7490601A/xx active Pending
- 2001-05-23 AR ARP010102458A patent/AR035336A1/es not_active Application Discontinuation
- 2001-05-23 SG SG2013055223A patent/SG193778A1/en unknown
- 2001-05-23 AU AU2001274906A patent/AU2001274906B2/en not_active Expired
- 2001-05-23 SG SG2008069635A patent/SG189556A1/en unknown
-
2002
- 2002-11-19 IL IL152934A patent/IL152934A/en active IP Right Grant
- 2002-11-22 NO NO20025627A patent/NO325352B1/no not_active IP Right Cessation
- 2002-12-12 ZA ZA200210101A patent/ZA200210101B/en unknown
- 2002-12-16 MA MA26957A patent/MA27292A1/fr unknown
-
2003
- 2003-06-20 US US10/602,691 patent/US7608597B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,142 patent/US20050124532A1/en not_active Abandoned
- 2003-06-20 US US10/602,136 patent/US7157441B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,976 patent/US7169766B2/en not_active Expired - Lifetime
-
2004
- 2004-06-01 ZA ZA200404305A patent/ZA200404305B/en unknown
-
2006
- 2006-07-21 AU AU2006203121A patent/AU2006203121B2/en not_active Expired
- 2006-07-21 AU AU2006203122A patent/AU2006203122B2/en not_active Expired
-
2007
- 2007-06-20 NO NO20073151A patent/NO332750B1/no not_active IP Right Cessation
-
2008
- 2008-12-31 IL IL196301A patent/IL196301A0/en active IP Right Grant
-
2009
- 2009-07-16 US US12/504,601 patent/US8299038B2/en not_active Expired - Fee Related
-
2010
- 2010-01-07 AU AU2010200077A patent/AU2010200077B2/en not_active Expired
-
2012
- 2012-09-20 US US13/623,674 patent/US20130017171A1/en not_active Abandoned
- 2012-10-10 NO NO20121146A patent/NO20121146L/no unknown
- 2012-12-28 US US13/730,669 patent/US10363265B2/en not_active Expired - Fee Related
-
2013
- 2013-02-27 JP JP2013036937A patent/JP5926211B2/ja not_active Expired - Lifetime
- 2013-07-29 US US13/953,687 patent/US20130315862A1/en not_active Abandoned
- 2013-10-10 JP JP2013212565A patent/JP5753563B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-22 UY UY0001035542A patent/UY35542A/es not_active Application Discontinuation
-
2016
- 2016-03-28 JP JP2016063156A patent/JP6240699B2/ja not_active Expired - Lifetime
-
2017
- 2017-07-28 JP JP2017146982A patent/JP2018012702A/ja active Pending
-
2018
- 2018-12-12 JP JP2018232209A patent/JP2019069968A/ja not_active Withdrawn
-
2019
- 2019-06-13 US US16/440,659 patent/US10758557B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004533401A5 (enExample) | ||
| JP2004510698A5 (enExample) | ||
| CA2409613A1 (en) | Methods and compositions for treating hepatitis c virus | |
| CA2410579A1 (en) | Methods and compositions for treating flaviviruses and pestiviruses | |
| US6815542B2 (en) | Nucleoside compounds and uses thereof | |
| JP2005533824A5 (enExample) | ||
| RU2525392C2 (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| KR20030032927A (ko) | 뉴클레오시드 화합물 및 이들의 용도 | |
| JP2004513070A5 (enExample) | ||
| RU2006105640A (ru) | Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с | |
| JP2010514768A5 (enExample) | ||
| JP2007501185A5 (enExample) | ||
| JP2006516949A5 (enExample) | ||
| AR043298A1 (es) | Prodrogas 2' y 3' de nucleosidos para tratar infecciones de flaviviridae, composiciones farmaceuticas, sus usos en la manufactura de medicamentos y metodos de tratamiento | |
| RU2006147216A (ru) | Бета-l-2` дезокси-нуклеозиды для лечения гепатита в | |
| JP2006505490A (ja) | ゲムシタビンｈｃｖ治療のための投薬計画 | |
| JP2012502956A (ja) | Ｈｃｖの大環状阻害剤とヌクレオシドの相乗性組み合わせ剤 | |
| JP2002543144A5 (enExample) | ||
| JP2011079840A (ja) | Ｂ型肝炎治療のための組合せ療法 | |
| PT1284720E (pt) | L-fmau para o tratamento de infecção viral por hepatite delta | |
| CN102775458A (zh) | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 | |
| RU2009128978A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| RU2003121401A (ru) | Комбинаторная терапия dapd и ингибиторами инозинмонофосфатдегидрогеназы, такими как рибавирин или микофеноловая кислота | |
| RU2005102096A (ru) | 2'и 3'-нуклеозидные пролекарства для лечения инфекций, вызываемых flaviviridae | |
| RU2020123449A (ru) | Фосфор(n)амидатацетальные и фосф(он)атацетальные соединения |